ATE503014T1 - Rna-amidate und thioamidateur rnai - Google Patents
Rna-amidate und thioamidateur rnaiInfo
- Publication number
- ATE503014T1 ATE503014T1 AT04818592T AT04818592T ATE503014T1 AT E503014 T1 ATE503014 T1 AT E503014T1 AT 04818592 T AT04818592 T AT 04818592T AT 04818592 T AT04818592 T AT 04818592T AT E503014 T1 ATE503014 T1 AT E503014T1
- Authority
- AT
- Austria
- Prior art keywords
- rna
- thioamidates
- amidates
- thioamidateur
- amidate
- Prior art date
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 title 1
- 108091030071 RNAI Proteins 0.000 title 1
- 229940059260 amidate Drugs 0.000 title 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 title 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 abstract 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 230000009368 gene silencing by RNA Effects 0.000 abstract 1
- 125000003473 lipid group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51676903P | 2003-11-04 | 2003-11-04 | |
| PCT/US2004/032780 WO2005047506A1 (en) | 2003-11-04 | 2004-11-03 | Rna amidates and thioamidates for rnai |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE503014T1 true ATE503014T1 (de) | 2011-04-15 |
Family
ID=34590131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04818592T ATE503014T1 (de) | 2003-11-04 | 2004-11-03 | Rna-amidate und thioamidateur rnai |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9133233B2 (de) |
| EP (1) | EP1694842B1 (de) |
| AT (1) | ATE503014T1 (de) |
| AU (1) | AU2004289975B2 (de) |
| CA (1) | CA2544349C (de) |
| DE (1) | DE602004031975D1 (de) |
| WO (1) | WO2005047506A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7356912B2 (en) | 2003-09-25 | 2008-04-15 | W.E.T. Automotive Systems, Ltd. | Method for ventilating a seat |
| ATE503014T1 (de) | 2003-11-04 | 2011-04-15 | Geron Corp | Rna-amidate und thioamidateur rnai |
| ES2868452T3 (es) | 2004-07-02 | 2021-10-21 | Geron Corp | Síntesis de monómeros nucleosídicos 5'fosforamidita 3 aminoprotegidos |
| US8785409B2 (en) | 2007-01-30 | 2014-07-22 | Geron Corporation | Compounds having anti-adhesive effects on cancer cells |
| WO2011048125A1 (en) | 2009-10-20 | 2011-04-28 | Santaris Pharma A/S | Oral delivery of therapeutically effective lna oligonucleotides |
| US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
| EP3868772A1 (de) | 2013-09-30 | 2021-08-25 | Geron Corporation | Phosphorodiamidat-rückgratverbindung für oligonukleotide |
| TWI769177B (zh) * | 2016-09-14 | 2022-07-01 | 美商艾洛斯生物製藥公司 | 經修飾之寡核苷酸及使用方法 |
| UA127701C2 (uk) | 2017-07-28 | 2023-12-06 | Джерон Корпорейшн | Спосіб лікування мієлодиспластичного синдрому (варіанти) |
| KR20200100033A (ko) * | 2017-09-14 | 2020-08-25 | 얀센 바이오파마, 인크. | 변형된 뉴클레오시드 포스포르아미다이트 |
| JP7650798B2 (ja) | 2018-11-29 | 2025-03-25 | ジェロン・コーポレーション | 骨髄異形成症候群を治療する方法 |
| WO2021198958A1 (en) * | 2020-04-01 | 2021-10-07 | Janssen Biopharma, Inc. | Nucleic acid polymers |
| WO2025207561A1 (en) * | 2024-03-27 | 2025-10-02 | Cepheid | Isothermal amplification using novel synthetic oligonucleotides |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2184375C (en) | 1994-03-18 | 2006-05-02 | Sergei M. Gryaznov | Oligonucleotide n3'-p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties |
| US5599922A (en) | 1994-03-18 | 1997-02-04 | Lynx Therapeutics, Inc. | Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties |
| US5726297A (en) | 1994-03-18 | 1998-03-10 | Lynx Therapeutics, Inc. | Oligodeoxyribonucleotide N3' P5' phosphoramidates |
| US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| US5684143A (en) | 1996-02-21 | 1997-11-04 | Lynx Therapeutics, Inc. | Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates |
| US5859233A (en) | 1996-02-21 | 1999-01-12 | Lynx Therapeutics, Inc. | Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates |
| EP1147204A1 (de) * | 1999-01-28 | 2001-10-24 | Medical College Of Georgia Research Institute, Inc. | Zusammensetzung und verfahren zur in vivo und in vitro abschwächung der genexpression mittels dobbelsträngigem rna |
| DE19956568A1 (de) * | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| KR20070112295A (ko) | 1999-09-10 | 2007-11-22 | 제론 코포레이션 | 올리고뉴클레오티드 엔3'→피5' 티오포스포라미데이트,이의 합성 및 용도 |
| GB9927444D0 (en) * | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| EP1272630A2 (de) * | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methoden und zusammensetzungen zur interferenz durch rna |
| EP1309726B2 (de) * | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Mediatoren von rns-interferenz, die rns-sequenzspezifisch sind |
| AU2003210671A1 (en) * | 2002-01-24 | 2003-09-02 | Chiron Corporation | Nek2 inhibitors |
| US7897752B2 (en) * | 2002-02-20 | 2011-03-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA) |
| EP1509540A4 (de) * | 2002-05-20 | 2005-10-26 | Immunex Corp | Claudinpolypeptide, polynucleotide und verfahren zu deren herstellung und verwendung |
| AU2003241621A1 (en) * | 2002-05-24 | 2003-12-12 | Isis Pharmaceuticals, Inc. | Oligonucleotides having modified nucleoside units |
| AU2003256323A1 (en) * | 2002-06-26 | 2004-01-19 | Chiron Corporation | Sos1 inhibitors |
| WO2004014312A2 (en) * | 2002-08-08 | 2004-02-19 | Sirna Therapeutics, Inc. | Small-mer compositions and methods of use |
| US20060116331A1 (en) * | 2002-09-27 | 2006-06-01 | Biomira, Inc. | Glycosylceramide analogues |
| EP2000160A3 (de) * | 2002-10-30 | 2009-03-11 | Gambro Lundia AB | Verfahren und Vorrichtungen zur Bestimmung der Dialyseeffizienz |
| US20060275769A1 (en) * | 2003-01-06 | 2006-12-07 | Oregon Health & Science University | Methods of treatment and diagnosis of kaposi's sarcoma (ks) and ks related diseases |
| WO2004080406A2 (en) | 2003-03-07 | 2004-09-23 | Alnylam Pharmaceuticals | Therapeutic compositions |
| CA2522637C (en) | 2003-04-17 | 2014-01-21 | Alnylam Pharmaceuticals, Inc. | Modified irna agents |
| US20060241072A1 (en) * | 2003-06-20 | 2006-10-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds for use in gene modulation |
| WO2006001810A2 (en) * | 2003-07-15 | 2006-01-05 | California Institute Of Technology | Improved inhibitor nucleic acids |
| SI3342425T1 (sl) | 2003-09-09 | 2020-04-30 | Geron Corporation | Modificirani oligonukleotidi za inhibicijo telomeraze |
| ATE503014T1 (de) | 2003-11-04 | 2011-04-15 | Geron Corp | Rna-amidate und thioamidateur rnai |
| ES2868452T3 (es) | 2004-07-02 | 2021-10-21 | Geron Corp | Síntesis de monómeros nucleosídicos 5'fosforamidita 3 aminoprotegidos |
| US9228189B2 (en) * | 2012-10-26 | 2016-01-05 | Geron Corporation | C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders |
-
2004
- 2004-11-03 AT AT04818592T patent/ATE503014T1/de not_active IP Right Cessation
- 2004-11-03 US US10/578,530 patent/US9133233B2/en active Active
- 2004-11-03 DE DE200460031975 patent/DE602004031975D1/de not_active Expired - Lifetime
- 2004-11-03 WO PCT/US2004/032780 patent/WO2005047506A1/en not_active Ceased
- 2004-11-03 CA CA2544349A patent/CA2544349C/en not_active Expired - Lifetime
- 2004-11-03 AU AU2004289975A patent/AU2004289975B2/en not_active Expired
- 2004-11-03 EP EP20040818592 patent/EP1694842B1/de not_active Expired - Lifetime
-
2015
- 2015-08-06 US US14/820,364 patent/US9822360B2/en not_active Expired - Fee Related
-
2017
- 2017-10-18 US US15/786,974 patent/US10655127B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US9822360B2 (en) | 2017-11-21 |
| WO2005047506A1 (en) | 2005-05-26 |
| AU2004289975B2 (en) | 2011-11-03 |
| CA2544349C (en) | 2020-02-18 |
| EP1694842B1 (de) | 2011-03-23 |
| US9133233B2 (en) | 2015-09-15 |
| CA2544349A1 (en) | 2005-05-26 |
| EP1694842A1 (de) | 2006-08-30 |
| US10655127B2 (en) | 2020-05-19 |
| US20160130580A1 (en) | 2016-05-12 |
| AU2004289975A1 (en) | 2005-05-26 |
| US20180119147A1 (en) | 2018-05-03 |
| US20070275919A1 (en) | 2007-11-29 |
| DE602004031975D1 (de) | 2011-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE503014T1 (de) | Rna-amidate und thioamidateur rnai | |
| WO2006113679A3 (en) | Delivery of sirna by neutral lipid compositions | |
| MX2009003548A (es) | Formulaciones que contienen lipidos. | |
| ATE534737T1 (de) | Gezielte abgabe von sirna | |
| MX2007004321A (es) | Micro acidos ribonucleicos. | |
| CY1112420T1 (el) | Ρυθμιση της γονιδιακης εκφρασης στα φυτα με μεσολαβηση dsrνα | |
| WO2014127287A8 (en) | Method for in vivo targeted mutagenesis | |
| WO2006138572A3 (en) | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates | |
| NZ596958A (en) | Improved lipid formulation | |
| EP2304026A4 (de) | Nanopartikelzusammensetzungen für ein system zur ausgabe von nukleinsäuren | |
| AR069821A1 (es) | Composiciones y metodos de uso de la interferencia de arn para el control de nematodos | |
| WO2006036916A3 (en) | Rnai modulation of apob and uses thereof | |
| WO2008131419A3 (en) | Glycoconjugates of rna interference agents | |
| WO2010057150A8 (en) | Releasable polymeric lipids for nucleic acids delivery system | |
| EP1824872A4 (de) | Rnai-modulation von mll-af4 und verwendungen dafür | |
| SG165394A1 (en) | Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification | |
| AU2014219019A8 (en) | Short interfering nucleic acid (siNA) molecules containing a 2' internucleoside linkage | |
| ATE483032T1 (de) | Verfahren zur herstellung von oligonukleotiden | |
| Nawani et al. | Actinomycetes: Role in biotechnology and medicine | |
| TR201820474T4 (tr) | Spesifik immün modülatör profilleri indükleyen tanımlı nükleotitler arası bağlar bağlamında rna sekansı motifleri. | |
| MX2024011671A (es) | Oligonucleotidos modificados | |
| WO2007014075A3 (en) | Rnai modulation of the rho-a gene in research models | |
| ATE550024T1 (de) | Gezielte oligonucleotid-zusammensetzungen zur modifizierung der genexpression | |
| WO2005054439A3 (en) | Small interfering rna (sirna)-mediated heritable gene manipulation in plants | |
| Su et al. | Neutral and negatively charged phosphate modifications altering thermal stability, kinetics of formation and monovalent ion dependence of DNA G‐Quadruplexes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |